Edmond de Rothschild Investment Partners is celebrating its 10th anniversary with plans to raise 500 million euros ($676.7 million) over the next 4 years and to increase assets under management to 1.3 billion euros. The firm currently manages 1 billion euros and is currently raising three funds: BioDiscovery 3, Winch 2 and Cabestan.
Created from an existing activity within the group at the end of 2002, Edmond de Rothschild Investment Partners celebrates its 10th anniversary.
Edmond de Rothschild Investment Partners currently manages EUR 1bn and is a leading private equity player in France and Europe in Growth Capital and Life Sciences. Despite a difficult environment since 2008, institutional and private investors have continued to support the teams in successfully raising 3 funds: BioDiscovery 3, Winch 2 and Cabestan. BioDiscovery 4 is also expected to reach its EUR 200m target very soon.
The company’s vision reflects the values of the Edmond de Rothschild Group and is founded on two pillars: positioning growth and innovation at the heart of value creation and assisting entrepreneurs and SMEs with their development projects. Thanks to this model, Edmond de Rothschild Investment Partners aims to raise EUR 500m over the next 4 years and to increase net assets under management to EUR 1.3bn. To reach this goal, the company will continue to expand its investment strategy to SMEs across Europe and broaden its investor base. These objectives are inscribed in the Edmond de Rothschild Group’s strategic plan for 2016.
The stability of the team, which comprises 24 experienced professionals based in Paris, Lyons and Milan, has helped maintain a coherent approach, a key factor in successful private equity investment. Edmond de Rothschild Investment Partners’ approach – assisting entrepreneurs in their growth strategies and in reorganising SME shareholding structures – requires such a long term vision.
“Since Edmond de Rothschild Investment Partners was founded, the Capital Development team has accompanied more than 70 entrepreneurs in ambitious projects including industrial investments, international development and external growth. Our portfolio companies are mainly French sector leaders like Nexira, Sergent Major and Voyageurs du Monde”, said Pierre-Yves Poirier, Partner, Capital Development.
Olivier Litzka, Partner, Life Sciences added: “Since 2005, we have invested via our BioDiscovery 2 and 3 funds more than EUR 200m in 25 innovative European biotech and medtech companies which have played a major role in discovering new treatments for serious illnesses. We have sold 6 of these companies through trade sales and 2 have been listed. Providing investors with access to a fascinating and meaningful sector through high-performance funds is doubly satisfying.”
CEO Pierre-Michel Passy, declared: “We are proud of how far we have come and are delighted with our sponsor’s support for the ambitious targets we have fixed, namely for raising EUR 500m and increasing our net assets under management to EUR 1.3bn within the next 4 years. We will continue to expand our investment strategy in SMEs across Europe and to broaden our investor base, a move that the BioDiscovery 4 fund raising has already set in motion.”
About Edmond de Rothschild Group
Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group which is specialised in asset management and private banking (EUR 125bn under management, 2,900 employees and 30 offices throughout the world). Founded in 1953, the Group has been chaired since 1997 by the founder’s son, Baron Benjamin de Rothschild
This document is for information only. The data, comments and analysis in this bulletin reflect the opinion of the Edmond de Rothschild Group and its affiliates with respect to the markets and their trends, regulation and tax issues, on the basis of its own expertise, economic analysis and information currently known to it. However, they shall not under any circumstances be construed as comprising any sort of undertaking or guarantee whatsoever on the part of the Edmond de Rothschild Group or its affiliates. Any investment in private equity and in capital development and venture capital funds involves specific risks like capital loss risk, discretionary management risk and liquidity risk. All potential investors should consult their service provider or advisor and exercise their own judgement independently of the Edmond de Rothschild Group on the risks inherent to each investment and its suitability to their own personal and financial circumstances. To this end, investors must acquaint themselves with each fund’s simplified prospectus/key investor information document available at www.edrip.fr or on request from the head office of Edmond de Rothschild Investment Partners.
Investors should note that the aforementioned funds are venture capital funds that are more lightly regulated. As such, they do not require approval from the French Financial Markets Authority (AMF) and may adopt exceptional investment rules.
Take your pick!
- Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
- VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.